obesity drugs

In a move that caps a heated contest for promising obesity therapies, Pfizer announced on Monday that it will purchase the U.S. biotech firm Metsera for approximately $10 billion in cash. The agreement puts an end to the bidding war that had seen the Danish pharmaceutical giant Novo Nordisk, the maker of...

Washington – The White House has announced a fresh agreement with several major pharmaceutical manufacturers that aims to reshape the way prescription drugs are priced in the United States. While the pact covers a broad spectrum of medications, its most immediate impact is expected to be felt by patients who...

President Donald J. Trump revealed a new arrangement with pharmaceutical giants Eli Lilly and Novo Nordisk that will dramatically reduce the cost of their best‑selling obesity treatments. Under the deal, the monthly price for the drugs—currently marketed as some of the most effective options for weight loss and diabetes management—will be capped...

President Donald Trump’s latest agreement with pharmaceutical giants Eli Lilly and Novo Nordisk could dramatically reshape the cost landscape for obesity treatments in the United States. The deal, announced from the Oval Office, sets a sliding scale of prices that varies by dosage, specific product, and the way a patient pays—whether through...

President Donald Trump unveiled a sweeping agreement with pharmaceutical giants Eli Lilly and Novo Nordisk that will dramatically cut the cost of their best‑selling weight‑loss medications for millions of Americans. Announced at a White House event, the deals are designed to make the drugs more affordable for patients covered by Medicare and...